These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36388925)

  • 1. Potential lipid-lowering effects of
    Lee YL; Lee SY
    Front Med (Lausanne); 2022; 9():1000428. PubMed ID: 36388925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 4-Week Intervention with
    Cho AR; Lee SY; Cho YH; Kim CM; Kim SG
    Evid Based Complement Alternat Med; 2018; 2018():5690816. PubMed ID: 29681977
    [No Abstract]   [Full Text] [Related]  

  • 3. LDL cholesterol-lowering effect of Daeshiho-tang in patients with dyslipidemia: A pilot randomized, double-blind, placebo-controlled trial.
    Noh JW; Lee BC
    Heliyon; 2023 Aug; 9(8):e19162. PubMed ID: 37654445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulmus macrocarpa Hance extract modulates intestinal microbiota in healthy adults: a randomized, placebo-controlled clinical trial.
    Kim K; Veerappan K; Woo N; Park B; Natarajan S; Chung H; Kim C; Park J
    J Microbiol; 2021 Dec; 59(12):1150-1156. PubMed ID: 34697783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
    Dogay Us G; Mushtaq S
    Lipids Health Dis; 2022 Sep; 21(1):84. PubMed ID: 36050695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulmus macrocarpa Hance modulates lipid metabolism in hyperlipidemia via activation of AMPK pathway.
    Han HJ; Song X; Yadav D; Hwang MS; Lee JH; Lee CH; Kim TH; Lee JJ; Kwon J
    PLoS One; 2019; 14(5):e0217112. PubMed ID: 31120956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
    J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
    Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.
    Santos JR; Saumoy M; Curran A; Bravo I; Llibre JM; Navarro J; Estany C; Podzamczer D; Ribera E; Negredo E; Clotet B; Paredes R;
    Clin Infect Dis; 2015 Aug; 61(3):403-8. PubMed ID: 25870325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
    Saltissi D; Morgan C; Rigby RJ; Westhuyzen J
    Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia.
    Upadya H; Prabhu S; Prasad A; Subramanian D; Gupta S; Goel A
    BMC Complement Altern Med; 2019 Jan; 19(1):27. PubMed ID: 30670010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of policosanol on borderline to mildly elevated serum total cholesterol levels: a prospective, double-blind, placebo-controlled, parallel-group, comparative study.
    Castaño G; Más R; Fernández J; López E; Illnait J; Fernández L; Mesa M
    Curr Ther Res Clin Exp; 2003 Sep; 64(8):522-37. PubMed ID: 24944402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study.
    Ruscica M; Pavanello C; Gandini S; Macchi C; Botta M; Dall'Orto D; Del Puppo M; Bertolotti M; Bosisio R; Mombelli G; Sirtori CR; Calabresi L; Magni P
    Nutr J; 2019 Feb; 18(1):13. PubMed ID: 30795775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
    Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
    Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.